ATAI adds MDMA biotech to growing list of psychedelic makers; Acadia adds $52.5M upfront pain buyout
For years, the biggest push in psychedelic drug development has been around MDMA, a party drug long thought to have potential benefits for patients with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
